{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:39:47Z","timestamp":1774528787198,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Research Group in Nephrology and Renal Replacement Therapy, Faculty of Medicine, Thammasat University"},{"name":"The Kidney Foundation of Thailand"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In patients on chronic hemodialysis, there is no standard protocol for maintenance iron supplementation. This study aimed to compare two fixed-dose intravenous (IV) iron protocols to reduce erythropoiesis-stimulating agents (ESA). We conducted a double-blinded, randomized controlled study on hemodialysis patients having ferritin levels between 200 and 700\u00a0ng\/dl and transferrin saturation values between 20 and 40%. Patients were assigned to receive either 100 or 200\u00a0mg of IV iron each month. ESA was adjusted every month to keep Hb between 10 and 12\u00a0g\/dl. ESA dose at 12\u00a0months was the primary outcome. The secondary outcomes were all-cause mortality, cardiovascular events, absolute iron deficiency anemia (IDA), blood transfusion, adverse events, and iron withholding rate. Of the 79 eligible patients, 40 received 100\u00a0mg of IV iron, while 39 received 200\u00a0mg. At month 12, the mean monthly ESA dose in the 100-mg IV iron group was 35,706\u2009\u00b1\u200921,637\u00a0IU, compared to 26,382\u2009\u00b1\u200914,983\u00a0IU in the 200-mg group (<jats:italic>P<\/jats:italic>\u2009=\u20090.03). IDA was found in twelve patients (30%) in the 100-mg group and four patients (10.5%) in the 200-mg group (<jats:italic>P<\/jats:italic>\u2009=\u20090.05). In each group, three patients died (<jats:italic>P<\/jats:italic>\u2009=\u20090.9). Hospitalization, venous access thrombosis, and infection rates were similar in both groups. The withholding rate of IV iron was higher in 200-mg group (25% vs<jats:italic>.<\/jats:italic> 64.1%), but the protocol compliance was found more in 100-mg group (50% vs. 28.2%) (<jats:italic>P<\/jats:italic>\u2009=\u20090.001). In conclusion, monthly 200-mg IV iron infusions significantly reduce ESA doses but have a higher withholding rate. (Funded by the Kidney Foundation of Thailand and the Research Group in Nephrology and Renal Replacement Therapy from the Faculty of Medicine, Thammasat University).<\/jats:p><jats:p>Thai Clinical Trials Registry number, TCTR20190707001.<\/jats:p>","DOI":"10.1038\/s41598-023-28440-3","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T15:03:07Z","timestamp":1674486187000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Maintenance intravenous iron in hemodialysis patients to minimize erythropoietin doses: a double-blinded, randomized controlled trial (the MAINTAIN IRON trial)"],"prefix":"10.1038","volume":"13","author":[{"given":"Suthiya","family":"Anumas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aphichat","family":"Chatkrailert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pichaya","family":"Tantiyavarong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,23]]},"reference":[{"key":"28440_CR1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.kint.2015.10.002","volume":"89","author":"IC Macdougall","year":"2016","unstructured":"Macdougall, I. C. et al. Iron management in chronic kidney disease: Conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) controversies conference. Kidney Int. 89, 28\u201339. https:\/\/doi.org\/10.1016\/j.kint.2015.10.002 (2016).","journal-title":"Kidney Int."},{"key":"28440_CR2","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1681\/ASN.2014090922","volume":"26","author":"DM Charytan","year":"2015","unstructured":"Charytan, D. M. et al. Considerations and challenges in defining optimal iron utilization in hemodialysis. J. Am. Soc. Nephrol. 26, 1238\u20131247. https:\/\/doi.org\/10.1681\/ASN.2014090922 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"28440_CR3","unstructured":"System, U. S. R. D. USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States (National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2020)."},{"key":"28440_CR4","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.kint.2021.03.020","volume":"99","author":"JL Babitt","year":"2021","unstructured":"Babitt, J. L. et al. Controversies in optimal anemia management: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) conference. Kidney Int. 99, 1280\u20131295. https:\/\/doi.org\/10.1016\/j.kint.2021.03.020 (2021).","journal-title":"Kidney Int."},{"key":"28440_CR5","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1681\/ASN.2019020213","volume":"31","author":"EK Batchelor","year":"2020","unstructured":"Batchelor, E. K., Kapitsinou, P., Pergola, P. E., Kovesdy, C. P. & Jalal, D. I. Iron deficiency in chronic kidney disease: Updates on pathophysiology, diagnosis, and treatment. J. Am. Soc. Nephrol. 31, 456\u2013468. https:\/\/doi.org\/10.1681\/ASN.2019020213 (2020).","journal-title":"J. Am. Soc. Nephrol."},{"key":"28440_CR6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1159\/000486968","volume":"47","author":"JB Wish","year":"2018","unstructured":"Wish, J. B. et al. Positive iron balance in chronic kidney disease: How much is too much and how to tell?. Am. J. Nephrol. 47, 72\u201383. https:\/\/doi.org\/10.1159\/000486968 (2018).","journal-title":"Am. J. Nephrol."},{"key":"28440_CR7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1053\/j.ackd.2008.12.008","volume":"16","author":"K Kalantar-Zadeh","year":"2009","unstructured":"Kalantar-Zadeh, K., Streja, E., Miller, J. E. & Nissenson, A. R. Intravenous iron versus erythropoiesis-stimulating agents: Friends or foes in treating chronic kidney disease anemia?. Adv. Chronic Kidney Dis. 16, 143\u2013151. https:\/\/doi.org\/10.1053\/j.ackd.2008.12.008 (2009).","journal-title":"Adv. Chronic Kidney Dis."},{"key":"28440_CR8","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1056\/NEJMoa1810742","volume":"380","author":"IC Macdougall","year":"2019","unstructured":"Macdougall, I. C. et al. Intravenous iron in patients undergoing maintenance hemodialysis. N. Engl. J. Med. 380, 447\u2013458. https:\/\/doi.org\/10.1056\/NEJMoa1810742 (2019).","journal-title":"N. Engl. J. Med."},{"key":"28440_CR9","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris, P. A. et al. Research electronic data capture (REDCap)\u2014A metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inform. 42, 377\u2013381. https:\/\/doi.org\/10.1016\/j.jbi.2008.08.010 (2009).","journal-title":"J. Biomed. Inform."},{"key":"28440_CR10","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris, P. A. et al. The REDCap consortium: Building an international community of software platform partners. J. Biomed. Inf. 95, 103208. https:\/\/doi.org\/10.1016\/j.jbi.2019.103208 (2019).","journal-title":"J. Biomed. Inf."},{"key":"28440_CR11","doi-asserted-by":"publisher","first-page":"205435812093339","DOI":"10.1177\/2054358120933397","volume":"7","author":"P Susantitaphong","year":"2020","unstructured":"Susantitaphong, P. et al. Effect of maintenance intravenous iron treatment on erythropoietin dose in chronic hemodialysis patients: A multicenter randomized controlled trial. Can. J. Kidney Health Dis. 7, 2054358120933397. https:\/\/doi.org\/10.1177\/2054358120933397 (2020).","journal-title":"Can. J. Kidney Health Dis."},{"key":"28440_CR12","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1186\/s12882-017-0745-9","volume":"18","author":"BM Robinson","year":"2017","unstructured":"Robinson, B. M. et al. Evaluating the effectiveness of IV iron dosing for anemia management in common clinical practice: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). BMC Nephrol. 18, 330. https:\/\/doi.org\/10.1186\/s12882-017-0745-9 (2017).","journal-title":"BMC Nephrol."},{"key":"28440_CR13","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/ki.2014.275","volume":"87","author":"GR Bailie","year":"2015","unstructured":"Bailie, G. R. et al. Data from the dialysis outcomes and practice patterns study validate an association between high intravenous iron doses and mortality. Kidney Int. 87, 162\u2013168. https:\/\/doi.org\/10.1038\/ki.2014.275 (2015).","journal-title":"Kidney Int."},{"key":"28440_CR14","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1681\/ASN.2005040423","volume":"16","author":"K Kalantar-Zadeh","year":"2005","unstructured":"Kalantar-Zadeh, K., Regidor, D. L., McAllister, C. J., Michael, B. & Warnock, D. G. Time-dependent associations between iron and mortality in hemodialysis patients. J. Am. Soc. Nephrol. 16, 3070\u20133080. https:\/\/doi.org\/10.1681\/ASN.2005040423 (2005).","journal-title":"J. Am. Soc. Nephrol."},{"key":"28440_CR15","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s11255-011-0028-5","volume":"44","author":"P Van Buren","year":"2012","unstructured":"Van Buren, P., Velez, R. L., Vaziri, N. D. & Zhou, X. J. Iron overdose: A contributor to adverse outcomes in randomized trials of anemia correction in CKD. Int. Urol. Nephrol. 44, 499\u2013507. https:\/\/doi.org\/10.1007\/s11255-011-0028-5 (2012).","journal-title":"Int. Urol. Nephrol."},{"key":"28440_CR16","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1016\/j.ekir.2022.05.008","volume":"7","author":"PC Thomson","year":"2022","unstructured":"Thomson, P. C. et al. An analysis of vascular access thrombosis events from the proactive IV iron therapy in hemodialysis patients trial. Kidney Int. Rep. 7, 1793\u20131801. https:\/\/doi.org\/10.1016\/j.ekir.2022.05.008 (2022).","journal-title":"Kidney Int. Rep."},{"key":"28440_CR17","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1681\/ASN.2019090972","volume":"31","author":"IC Macdougall","year":"2020","unstructured":"Macdougall, I. C. et al. Intravenous iron dosing and infection risk in patients on hemodialysis: A prespecified secondary analysis of the PIVOTAL trial. J. Am. Soc. Nephrol. 31, 1118\u20131127. https:\/\/doi.org\/10.1681\/ASN.2019090972 (2020).","journal-title":"J. Am. Soc. Nephrol."},{"key":"28440_CR18","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1093\/ckj\/sfv142","volume":"9","author":"L Del Vecchio","year":"2016","unstructured":"Del Vecchio, L., Longhi, S. & Locatelli, F. Safety concerns about intravenous iron therapy in patients with chronic kidney disease. Clin. Kidney J. 9, 260\u2013267. https:\/\/doi.org\/10.1093\/ckj\/sfv142 (2016).","journal-title":"Clin. Kidney J."},{"key":"28440_CR19","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2215\/CJN.05390517","volume":"13","author":"I Hougen","year":"2018","unstructured":"Hougen, I. et al. Safety of intravenous iron in dialysis: A systematic review and meta-analysis. Clin. J. Am. Soc. Nephrol. 13, 457\u2013467. https:\/\/doi.org\/10.2215\/CJN.05390517 (2018).","journal-title":"Clin. J. Am. Soc. Nephrol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-28440-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-28440-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-28440-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T15:05:26Z","timestamp":1674486326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-28440-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,23]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["28440"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-28440-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,23]]},"assertion":[{"value":"13 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1287"}}